000171639 001__ 171639
000171639 005__ 20260527123126.0
000171639 0247_ $$2doi$$a10.1177/00031348231175452
000171639 0248_ $$2sideral$$a149381
000171639 037__ $$aART-2023-149381
000171639 041__ $$aeng
000171639 100__ $$aMoreno Djadou, Teresa$$uUniversidad de Zaragoza
000171639 245__ $$aCytoreductive Surgery and Hyperthermic Peritoneal Chemotherapy in Appendiceal and Colorectal Cancer: Outcomes and Survival
000171639 260__ $$c2023
000171639 5203_ $$aBackground
We reviewed outcomes following cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with appendiceal or colorectal neoplasms and evaluated key prognostic indicators for treatment.
Methods
All patients who underwent cytoreductive surgery/HIPEC for appendiceal and colorectal neoplasms were identified from an IRB-approved database. Patient demographics, operative reports, and postoperative outcomes were reviewed.
Results
110 patients [median age 54.5 (18-79) years, 55% male] were included. Primary tumor location was colorectal (58; 52.7%) and appendiceal (52; 47.3%). 28.2%, .9%, and 12.7% had right, left, and sigmoid tumors, respectively; 11.8% had rectal tumors. 12/13 rectal cancer patients underwent preoperative radiotherapy. Mean Peritoneal Cancer Index was 9.6 ± 7.7; complete cytoreduction was achieved in 90.9%. 53.6% developed postoperative complications. Reoperation, perioperative mortality, and 30-day readmission rates were 1.8%, .09%, and 13.6%, respectively. Recurrence at a median of 11.1 months was 48.2%; overall survival at 1 and 2 years was 84% and 56.8%, respectively; disease-free survival was 60.8% and 33.7%, respectively, at a median follow-up of 16.8 (0-86.8) months. Univariate analysis of preoperative chemotherapy, primary malignancy location, primary tumor perforated or obstructive, postoperative bleeding complication, and pathology of adenocarcinoma, mucinous adenocarcinoma and negative lymph nodes were identified as possible predictive factors of survival. Multivariate logistic regression analysis showed that preoperative chemotherapy (P < .001), perforated tumor (P = .003), and postoperative intra-abdominal bleeding (P < .001) were independent prognostic indicators for survival.
Conclusions
Cytoreductive surgery/HIPEC for colorectal and appendiceal neoplasms has low mortality and high completeness of cytoreduction score. Preoperative chemotherapy, primary tumor perforation, and postoperative bleeding are adverse risk factors for survival.
000171639 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000171639 590__ $$a1.0$$b2023
000171639 591__ $$aSURGERY$$b209 / 292 = 0.716$$c2023$$dQ3$$eT3
000171639 592__ $$a0.413$$b2023
000171639 593__ $$aSurgery$$c2023$$dQ2
000171639 593__ $$aMedicine (miscellaneous)$$c2023$$dQ3
000171639 594__ $$a1.4$$b2023
000171639 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000171639 700__ $$aPoh, Keat Seong
000171639 700__ $$aYellinek, Shlomo
000171639 700__ $$aFayazzadeh, Hana
000171639 700__ $$aEl-Hayek, Kevin
000171639 700__ $$aSimpfendorfer, Conrad H.
000171639 700__ $$aDaSilva, Giovanna
000171639 700__ $$aWexner, Steven D.
000171639 7102_ $$11013$$2090$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Cirugía
000171639 773__ $$g89, 12 (2023), 5757-5767$$pAm. surgeon$$tAMERICAN SURGEON$$x0003-1348
000171639 8564_ $$s608353$$uhttps://zaguan.unizar.es/record/171639/files/texto_completo.pdf$$yVersión publicada
000171639 8564_ $$s2080176$$uhttps://zaguan.unizar.es/record/171639/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000171639 909CO $$ooai:zaguan.unizar.es:171639$$particulos$$pdriver
000171639 951__ $$a2026-05-27-11:25:33
000171639 980__ $$aARTICLE